Neurocrine Biosciences, Inc. · NBIX · FY2025 Q4 · Calendar Q1 2026
Neurocrine posts record year as INGREZZA and CRENESSITY drive growth
The call supports a growth case led by INGREZZA and the early CRENESSITY launch, with pipeline investment extending the opportunity beyond current products. Evidence to monitor includes new-patient growth and formulary access, while pricing, competition and CRENESSITY adoption pace temper the outlook.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about NBIX FY2025 Q4
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter discussion, management emphasized full-year results and a larger CRENESSITY footprint, detailed a Q2 sales-force expansion and AI-assisted prescriber targeting, and announced the divestiture of its U.K. and European rare commercial business. Management also described Phase II work on next-generation VMAT2 assets and Phase III readouts planned for 2027.
Guidance delta
Guidance sentiment was maintained. Management reiterated its 2026 INGREZZA sales outlook and expected growth; it did not provide specific 2026 CRENESSITY sales guidance.
Key takeaways
- INGREZZA remains the main established growth driver, with management guiding to continued growth in 2026.
- CRENESSITY's first year showed meaningful uptake, but management did not provide a specific 2026 sales target.
- Pipeline progress includes next-generation VMAT2 programs and Phase III neuropsychiatry programs with readouts planned for 2027.
- The earnings scorecard shows results above consensus; the subsequent event-window share move underperformed the benchmark.
Management priorities
- Expand CRENESSITY reach through sales-force deployment and AI-assisted targeting of additional prescribers.
- Sustain INGREZZA volume growth through sales execution and formulary access.
- Advance clinical programs and generate data across the pipeline.
Follow NBIX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationNeurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing…
Historical context
All NBIX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
| BMRN BioMarin Pharmaceutical Inc. | FY2026 Q3 · Calendar Q4 2026 | +376.0% | -1.8% | BioMarin’s Q3 growth meets a lower full-year outlook |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
Latest beats and misses
Who reports nextBeat on EPS
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the NBIX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T10:10:50.926579+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T10:10:50.923731+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.